Could GLP-1 agonists be used as chemotherapy in the treatment of hepatocellular carcinoma?

Postgraduate Thesis uoadl:2970894 94 Read counter

Κατεύθυνση Σακχαρώδης Διαβήτης και Παχυσαρκία
Library of the School of Health Sciences
Deposit date:
Papageorgiou Eleni
Supervisors info:
Νικόλαος Τεντολούρης , Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Μακρυλάκης , Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Αλέξανδρος Κόκκινος ,Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Μπορούν οι GLP-1 αγωνιστές να χρησιμοποιηθούν ως χημειοθεραπευτικά στη θεραπεία του ηπατοκυτταρικού καρκίνου;
Translated title:
Could GLP-1 agonists be used as chemotherapy in the treatment of hepatocellular carcinoma?
BACKGROUND-PURPOSE: Ηepatocellular carcinoma (HCC) ranks fifth as cause of cancer and fourth of cancer related death worldwide. Widespread use of GLP-1 agonists, for the treatment of diabetes mellitus type 2 (SD2),steatohepatitis and obesity which are emerging risk factors of HCC, has risen evidence for their potential beneficial use in treating HCC.
The purpose of this systematic review is to investigate whether GLP-1 agonists show anticancer effect on development and metastatic attitude of HCC.
MATERIAL-METHOD: Search was performed in global data bases for finding papers concerning the effect of GLP-1 agonists in treating HCC, according to the guide lines of PRISMA statement (Moher 2010). Based on inclusion and exclusion criteria, 5 papers were collected for systematic review, including in vitro experiments in hepatocellular carcinoma cell lines and in vivo ones in mice, No studies in patients with HCC were found.
RESULTS : GLP-1 agonists show a statistically significant effect on inhibiting the proliferation of hepatocellular carcinoma cell lines, through the mechanisms of autophagy, senescence and immune necrosis. Moreover, they suppress cell migration. The role of apoptosis is controversial. Their action is mediated via activation and inhibition of important signaling pathways, involved in hepatocarcinogenesis, including mTOR, TGF-β and JNK.
CONCLUSIONS: This review indicates that GLP-1 agonists exhibit antitumor effect on hepatocellular carcinoma cell lines, when they grow in cultures, suppressing their proliferation and migration.
Well-designed studies in human with HCC are required to further clarify the results of this review.
Main subject category:
Health Sciences
Ηepatocellular carcinoma, GLP-1 agonists, Liraglutide, Autophagy, mTOR
Number of index pages:
Contains images:
Number of references:
Number of pages:
Papageorgiou_Eleni_MSc.pdf.pdf (2 MB) Open in new window